Literature DB >> 11023327

Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.

W G Simpson, P Twomey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023327      PMCID: PMC1118516     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  9 in total

Review 1.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

2.  Lifetime risk of developing coronary heart disease.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

3.  Risk in cardiovascular disease. Absolute cardiovascular risk is not most appropriate measure to use.

Authors:  D Albert
Journal:  BMJ       Date:  2000-07-15

4.  Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group.

Authors:  R M Norris
Journal:  BMJ       Date:  1998-04-04

5.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

6.  Lifetime risk of developing coronary heart disease.

Authors:  D M Lloyd-Jones; M G Larson; A Beiser; D Levy
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

7.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors:  M R Law; N J Wald; S G Thompson
Journal:  BMJ       Date:  1994-02-05

8.  Cardiovascular disease risk profiles.

Authors:  K M Anderson; P M Odell; P W Wilson; W B Kannel
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

9.  The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity.

Authors:  S A Grover; M Abrahamowicz; L Joseph; C Brewer; L Coupal; S Suissa
Journal:  JAMA       Date:  1992-02-12       Impact factor: 56.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.